SMTL ID : 5c37.1 (1 other biounit)

Structure of the beta-ketoacyl reductase domain of human fatty acid synthase bound to a spiro-imidazolone inhibitor

Coordinates

PDB Format

Method

X-RAY DIFFRACTION 2.30 Å

Oligo State

monomer

Ligands

1 x NDP: NADPH DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE(Non-covalent)

NDP.1: 33 residues within 4Å: Chain A: G.433, G.436, G.437, F.438, G.439, T.457, S.458, R.459, S.460, N.487, I.488, S.489, N.512, L.513, A.514, V.515, V.516, P.536, K.537, F.561, S.562, S.563, V.564, Y.576, N.580, W.602, G.603, A.604, I.605, G.609, I.610, L.611 Ligands: 4XN.2 24 PLIP interactions: 24 interactions with chain A Hydrophobic interactions: A:W.602, A:I.605 Hydrogen bonds: A:G.433, A:G.437, A:F.438, A:S.458, A:R.459, A:N.487, A:N.487, A:A.514, A:V.515, A:K.537, A:F.561, A:Y.576, A:I.605, A:I.610, A:L.611 Water bridges: A:G.436, A:G.436, A:G.436, A:G.439, A:R.459, A:G.609 Salt bridges: A:R.459

1 x 4XN: 6-{[(3R)-1-(cyclopropylcarbonyl)pyrrolidin-3-yl]methyl}-5-[4-(1-methyl-1H-indazol-5-yl)phenyl]-4,6-diazaspiro[2.4]hept-4-en-7-one(Non-covalent)

4XN.2: 24 residues within 4Å: Chain A: E.8, P.155, H.156, P.157, L.158, L.517, S.563, V.564, S.565, R.568, G.569, N.570, Q.573, Y.576, W.602, G.603, A.604, I.610, L.611, V.622, S.623, T.625, F.651 Ligands: NDP.1 12 PLIP interactions: 12 interactions with chain A Hydrophobic interactions: A:P.157, A:L.517, A:V.564, A:V.564, A:R.568, A:V.622 Hydrogen bonds: A:S.563, A:S.565, A:R.568, A:N.570, A:S.623 pi-Stacking: A:F.651

1 x CL: CHLORIDE ION(Non-functional Binders)

CL.3: 6 residues within 4Å: Chain A: N.127, P.129, R.297, R.354, N.360, R.363 Ligand excluded by PLIP

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Lu, T. et al., Design and Synthesis of a Series of Bioavailable Fatty Acid Synthase (FASN) KR Domain Inhibitors for Cancer Therapy. to be published

Release Date

2016-06-22

Peptides

Fatty acid synthase: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Fatty acid synthase

Related Entries With Identical Sequence